Evidence map›Paper›PMID 40463102›Full record

ArticlebioRxiv : the preprint server for biology2025

Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines.

Amin Addetia, Alexandra Schäfer, Kaitlin Sprouse, Adian Valdez, Ashley Taylor, Mary-Jane Navarro, Jack T Brown, Elizabeth M Leaf, Marcos C Miranda, Alexandra C Walls and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Improving the immunogenicity ofFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Amin AddetiaDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kaitlin SprouseDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Adian ValdezDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Ashley TaylorDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Mary-Jane NavarroDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Jack T BrownDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Elizabeth M LeafDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Marcos C MirandaDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Jimin LeeDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Catherine TreichelDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Isabelle WilloughbyDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
John PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David R MartinezDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, 06511.
Blue VesariDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Rashmi RavichandranDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Albert J SeoDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Benjamin MerzDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Emily BeirneDepartment of Laboratory Medicine and Pathology, Seattle, WA 98195, USA.
Samantha ZepedaDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Anthony CookBIOQUAL, Inc., Rockville, MD 20852, USA.
Laurent PessaintBIOQUAL, Inc., Rockville, MD 20852, USA.
Ankur SharmaBIOQUAL, Inc., Rockville, MD 20852, USA.
Darin EdwardsModerna Inc., Cambridge, MA 02139, USA.
Kunse LeeDepartment of R&D, SK Bioscience, Seongnam, Republic of Korea.
Kelly SmithDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, 06511.
Tyler StarrDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Ralph BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Neil P KingDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6019-8675

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3M
Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4M
Gates Foundation INV-010680NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Vaccines against emerging SARS-CoV-2 variants and sarbecoviruses with pandemic potential must elicit a robust humoral immune response in a population imprinted with the SARS-CoV-2 spike (S) protein. Here, we designed protein nanoparticle (NP) vaccines co-displaying the SARS-CoV-2 BA.5, SARS-CoV-1, and BtKY72 receptor-binding domains (RBDs) with or without the Wuhan-Hu-1 (Wu) RBD. We show that these vaccines elicit cross-reactive and broadly neutralizing plasma antibody responses against SARS-CoV-2 variants and sarbecoviruses in naive and pre-immune animals. Immunization with multivalent RBD-NPs overcomes immune imprinting and elicits neutralizing antibodies and memory B cells specific for the BA.5, SARS-CoV-1, and BtKY72 RBDs in mRNA-1273-vaccinated non-human primates. Multivalent RBD-NPs outperform a monovalent Wu RBD-NP vaccine by providing superior protection in mice and non-human primates challenged with the vaccine-mismatched SARS-CoV-2 XBB.1.5 or the pre-emergent RsSHC014. These data support the use of multivalent RBD-NP vaccines for SARS-CoV-2 variants and sarbecoviruses in naive and pre-immune populations.

Identifiers

PMID40463102
PMCPMC12132498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.